Page last updated: 2024-08-23

cabergoline and Weight Loss

cabergoline has been researched along with Weight Loss in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Grattan, D; Manning, PJ; Manning, T; Merriman, T; Sutherland, W; Williams, S	1
Gibson, CD; Karmally, W; Korner, J; McMahon, DJ; Wardlaw, SL	1
Freda, PU; Korner, J; Lo, J; Wardlaw, SL	1
Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM	1

Trials

2 trial(s) available for cabergoline and Weight Loss

Article	Year
Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline. International journal of obesity (2005), 2018, Volume: 42, Issue:11 Topics: Adult; Cabergoline; Diet, Reducing; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Secondary Prevention; Treatment Outcome; Weight Gain; Weight Loss; Young Adult	2018
Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:4 Topics: Adolescent; Adult; Blood Glucose; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Glucose Tolerance Test; Humans; Hyperprolactinemia; Male; Middle Aged; Obesity; Pilot Projects; Prolactin; Weight Loss; Young Adult	2012

Article

Year

Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline.

International journal of obesity (2005), 2018, Volume: 42, Issue:11

Topics: Adult; Cabergoline; Diet, Reducing; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Secondary Prevention; Treatment Outcome; Weight Gain; Weight Loss; Young Adult

2018

Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.

Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:4

Topics: Adolescent; Adult; Blood Glucose; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Glucose Tolerance Test; Humans; Hyperprolactinemia; Male; Middle Aged; Obesity; Pilot Projects; Prolactin; Weight Loss; Young Adult

2012

Other Studies

2 other study(ies) available for cabergoline and Weight Loss

Article	Year
Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obesity research, 2003, Volume: 11, Issue:2 Topics: Anti-Obesity Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Weight Loss	2003
The treatment of polycystic ovary syndrome. Minerva ginecologica, 2004, Volume: 56, Issue:1 Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss	2004

Article

Year

Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.

Obesity research, 2003, Volume: 11, Issue:2

Topics: Anti-Obesity Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Weight Loss

2003

The treatment of polycystic ovary syndrome.

Minerva ginecologica, 2004, Volume: 56, Issue:1

Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss

2004